| abstract |
Disclosed is the use of at least one pyrazolo[1,5-a]pyrimidine compound selected from a group as outlined in figure 1, or a pharmaceutically acceptable salt, solvate or ester of the compound, for the manufacture of a medicament for treating, or slowing the progression of, a disease by inhibiting a Checkpoint kinase, wherein the disease is a proliferative disease, autoimmune disease, viral disease, fungal disease, neurological/neurodegenerative disorder, arthritis, inflammation, anti-proliferative disease, neuronal disease, alopecia or cardiovascular disease. Also disclosed is a pyrazolo[1,5-a]pyrimidine compound selected from the group or a pharmaceutically acceptable salt or solvate thereof. |